End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
28.79 USD | -3.57% | -0.38% | +35.82% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The stock, which is currently worth 2025 to 0.52 times its sales, is clearly overvalued in comparison with peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company does not generate enough profits, which is an alarming weak point.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+35.82% | 26.94B | - | ||
+13.18% | 53.05B | B | ||
+12.55% | 52.93B | B+ | ||
+26.50% | 48.37B | B+ | ||
+21.05% | 45.08B | B+ | ||
+22.48% | 39.43B | B | ||
+18.33% | 33.46B | B | ||
+42.08% | 29.24B | A | ||
+0.42% | 29.21B | B | ||
-8.62% | 27.34B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 8750 Stock
- DLIC.Y Stock
- Ratings Dai-ichi Life Holdings, Inc.